I
InMed Pharmaceuticals Inc. (INM)
NCM – Real Time Price. Currency in USD
0.66
+0.03 (5.48%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.66
+0.03 (5.48%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 3.12 | 2.52 | 10 | |
| Quick ratio | 3.12 | 1.78 | 10 | |
| Debt to Equity | 0.06 | -0.80 | 9.0 | |
| Debt to Assets | 0.05 | 0.73 | 9.0 | |
| Interest coverage | N/A | -13.90 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 1M | 4M | 5M | 5M | 3M |
| Gross Profit | 68K | 1M | 496K | 1M | 584K |
| Operating Income | -14M | -8M | -8M | -8M | -9M |
| Net Income | -19M | -8M | -8M | -8M | -9M |
| EBITDA | -13M | -8M | -8M | -7M | -8M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | N/A | 1.0 |
| Next quarter | N/A | N/A | 1.0 |
| Current year | N/A | N/A | 1.0 |
| Next year | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -99.99 | -46.24 | N/A | 25.2 | 3.3 |
| Y/Y | 999 | -39.85 | N/A | -12.62 | 3.3 |
| 3y average | 99.43 | 18.12 | 79.56 | 15.79 | 9.5 |
| 5y average | 459.26 | -8.4 | 45.87 | -8.83 | 5.5 |
| Weighted average score | 5.4 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $5.2M significantly exceed its total debt $420.1K, ensuring strong financial flexibility
Total current assets $6.9M exceed Total current liabilities $2.2M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (-0.8), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$1.8M limits the company's ability to reinvest or pay down debt